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Background: The 2017 European Society of Cardiology guidelines for valvular heart disease included 
changes in the definition of severe aortic stenosis. We wanted to evaluate its influence on management 
decisions in asymptomatic patients with moderate-severe aortic stenosis.  
Methods: We reclassified the aortic stenosis(AS) severity of the participants of the PRIMID-AS study, 
using the 2017 guidelines, determined their risk of reaching a clinical endpoint (valve replacement for 
symptoms, hospitalisation or cardiovascular death) and evaluated the prognostic value of aortic 
valve(AV) Calcium score and biomarkers. Patients underwent echocardiography, cardiac magnetic 
resonance imaging, exercise tolerance testing (ETT) and biomarker assessment. 
Results: Of the 174 participants, 45% (56/124) classified as severe AS were reclassified as moderate 
AS. This Reclassified group was similar to the original moderate group in clinical characteristics, 
gradients, calcium scores and remodelling parameters. There were 47 primary endpoints (41 valve 
replacement, 1 death, 5 hospitalisations - 1 chest pain, 2 dyspnoea, 1 heart failure, 1 syncope) over 
368±156 days follow-up. The severe and Reclassified groups had higher risk compared to moderate 
group (adjusted hazard ratio 4.95 (2.02-12.13) and 2.78 (1.07-7.22) respectively), with the Reclassified 
group demonstrating an intermediate risk. A mean pressure gradient (MPG)≥31mmHg had a 7× higher 
risk of the primary endpoint in the Reclassified group. AV Calcium score was more prognostic in 
females and low valve area, but not after adjusting for gradients. NTproBNP and myocardial perfusion 
reserve were associated with the primary endpoint, but not after adjusting for positive ETT. Troponin 
was associated with cardiovascular death or unplanned hospitalisations.  
Conclusions: Reclassification of asymptomatic severe AS into moderate AS was common using ESC 
2017 guidelines. This group had an intermediate risk of reaching the primary endpoint. Exercise testing, 
multi-modality imaging and lower MPG threshold of 31mmHg may improve risk stratification.  
Clinical Trial Registration Information: clinicaltrials.gov - NCT01658345 
Keywords: aortic stenosis, aortic valve calcification, exercise tolerance test, calcium score  
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Clinical Perspective 
Patients with aortic stenosis (AS) valve area< 1.0cm2, low gradient (mean <40mmHg) and normal flow 
(>35ml/m2) are now downgraded from severe to moderate AS in the 2017 European guidelines for 
valvular heart disease. We applied the new criteria to an initially asymptomatic cohort of moderate-
severe AS patients to ascertain the extent of the reclassification. We found that 45% of patients 
previously classified as severe AS were downgraded to moderate AS. These reclassified patients had 
more than a 2.5 higher risk of progression to spontaneous symptoms, hospitalisation or death, compared 
to patients with moderate AS, but this risk was lower than patients with severe AS (high gradient or low 
gradient low flow). A mean pressure gradient ≥31mmHg identified reclassified patients at highest risk 
of progression to symptoms (7-fold higher relative risk). Exercise testing remained a useful independent 
predictor of symptom progression in the new definition of severe AS, but not in the reclassified group. 
Therefore, with asymptomatic AS patients with low valve area but low gradients, clinicians should use 
an integrated approach with multiparametric assessment (Calcium score of aortic valve, 
Transesophageal echocardiography), and scrutinize the measurements carefully, recognizing that this 





The management of asymptomatic patients with severe aortic stenosis (AS) is controversial. Symptoms 
herald a malignant phase1. Arguably, aortic valve replacement (AVR) should occur before symptom 
onset or irreversible fibrosis, measurable on cardiovascular magnetic resonance imaging (CMR) as late 
gadolinium enhancement (LGE), if long-term outcomes are to be improved2. Natriuretic peptides and 
high-sensitivity troponin (HsTNI) help identify asymptomatic patients at risk, but high values also 
associate with higher perioperative risk3 and post-operative outcome4, 5. Better tools to optimize surgical 
timing are urgently needed. 
Both the 2012 European and 2014 American guidelines define AS in a similar way6, 7. However, the 
updated 2017 European guidelines places emphasis on pressure gradients (see Table-1). In low gradient 
(mean pressure gradient, MPG<40mmHg) AS with preserved ejection fraction (EF), an integrated 
approach, including aortic valve calcium score (AV-calcium score) assessment by multi-detector 
computed tomography (MDCT), is suggested8. Thus, low gradient severe AS is reclassified as moderate 
AS, apart from low flow status (stroke volume index, SVI≤35ml/m2) with high calcium scores, which 
remain as severe AS. Whether this new classification improves risk stratification and identification of 
those who would benefit from AVR in initially asymptomatic patients is unknown.  
The aims of this study were: (i) to use the updated European 2017 guidelines to reclassify patients in 
the ‘Prognostic Importance of Microvascular Dysfunction in asymptomatic patients with AS’ 
(PRIMID-AS) study9, previously defined as severe AS based on the European 2012 guidelines; (ii) to 
ascertain whether the  re-classification, troponin, natriuretic peptides or exercise testing (ETT) can help 
guide management decisions and (iii) to evaluate the additive prognostic value of AV-Calcium scores. 
Methods 
The data that support the findings of this study are available from the corresponding author upon 
reasonable request. 
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The PRIMID-AS study was a prospective, observational, multi-centre study of asymptomatic moderate 
to severe AS in the UK, comparing myocardial perfusion reserve (MPR) with exercise tolerance test 
(ETT)9, 10. Briefly, inclusion criteria were ≥2 of: aortic valve area (AVA)<1.5cm2, peak gradient 
>36mmHg or MPG>25mmHg, and willingness to accept AVR if symptoms developed. Exclusion 
criteria were: previous coronary artery bypass grafting or valve surgery, absolute contraindications to 
CMR or adenosine, other severe valve disease, EF≤40%, recent myocardial infarction (<6 months), 
persistent atrial fibrillation and planned surgery. All participants provided written informed consent. 
The study had National Research Ethics Service approval and complied with the Declaration of 
Helsinki. 
Investigations 
All patients underwent transthoracic echocardiography, AV-Calcium scoring, symptom-limited bicycle 
ETT, venous blood sampling for biomarker analysis and 3T multi-parametric CMR (including stress 
and rest first-pass perfusion imaging, pre- and post-contrast T1 mapping and LGE), as previously 
published9, 10. For the purposes of this paper, a positive ETT was defined according to the 2017 
European guidance: ‘any AS symptom on exercise testing or fall in BP below baseline during exercise’8. 
Core lab CMR image analysis was undertaken by a single blinded observer (AS). SVI was calculated 
on echocardiography as the product of the left ventricular outflow tract area and its velocity time integral 
and indexed to body surface area11, 12. MDCT images through the AV were acquired in the diastolic 
phase of the cardiac cycle, using sequential acquisitions of 3mm slices in full inspiration. AV-calcium 
score was calculated using the Agatston method13.  
Biomarker Analysis 
Plasma was processed within 4 hours of venepuncture and stored at -80°C. Biomarker batch analysis 
was performed at the end of the study. N-Terminal pro-Brain Natriuretic Peptide (NTproBNP) was 
analysed using our in-house non-competitive immunoassay14. HsTNI was analysed using the 
ARCHITECT STAT high-sensitivity assay (Abbott Laboratories, Abbott Park, Il, USA). 
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Follow-up and endpoints 
Patients had a minimum follow-up of 12 months or until reaching the primary endpoint. The primary 
endpoint was a composite of AVR for spontaneous symptoms or hospitalisation with heart failure, chest 
pain, syncope or cardiovascular death. Endpoints were adjudicated by 2 independent cardiologists. 
Management decisions were left to the attending physicians. The results of all research tests were kept 
blinded from the clinical teams, to avoid the results biasing the decision-making. ETT was deliberately 
not used to define symptom status in this study, as exercise-induced symptoms was considered a class 
IIB(C) indication in the American guidelines at the time of the study design15, and it was not routinely 
used in our institution. More importantly, the aim of the original study was to compare ETT to MPR in 
predicting outcomes and spontaneous symptom onset. 
Definitions 
The differences between the 2012 and 2017 European guidelines are shown in Table-1. Using the new 
definitions, 3 groups emerged: “Moderate” (moderate by both criteria); “Reclassified” (severe by 2012 
but moderate by 2017 criteria); and “Severe” (severe by both criteria). Those with low gradient severe 
AS were reclassified as moderate if they had normal flow, or low flow with low AV calcium scores as 
shown in Table-1. Sex-adjusted AV-Calcium score (AVCalcIndex) was calculated by dividing the 
calcium score by the cut-off for the sex (2000/1200AU for males/females). 
Statistical Analyses 
Normality was assessed using Kolmogorov-Smirnoff tests, histograms and Q-Q plots. Parametric data 
are expressed as mean±standard deviation. Non-parametric data are expressed as median [25th, 75th 
centile]. Discrete variables are presented as number (%). Continuous variables were compared between 
groups with the one-way ANOVA or Kruskal-Wallis test as appropriate. A Bonferroni correction was 
applied for post-hoc comparisons. The χ2 test or Fisher’s exact test was used for categorical variables. 
Where appropriate, variables were Log2-transformed for modelling purposes. AV Calcium scores were 
transformed with Logn(AV Calcium score+1) to accommodate zero-calcium scores for modelling. Cox 
regression analyses were performed to ascertain hazard ratios (HR) of reaching the endpoint, and 
expressed as HR (95% Confidence Interval,CI). Binary variables were modelled as continuous 
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variables. Non-binary categorical variables were modelled as categorical variables to the reference 
group. For Cox and Fine-Gray multivariable analyses, variables of interest were adjusted for 
confounding covariates previously known to be associated with the end-point, with limited number of 
covariates to avoid overfitting. Collinearity of covariates in models was assessed by calculating the 
variance inflation factor, and values >2.5 were considered collinear. With collinear variables, only the 
most significant collinear covariate in univariate association (by p-value) was used in any model. The 
assumption of linearity was assessed by plotting Martingale residuals against continuous variables to 
ensure the correct functional form was used. Proportional hazards assumption was tested using statistics 
and graphs based on the Schoenfeld residuals. Where competing events were important confounders 
(e.g. surgery preventing hospitalisation or death), Fine-Gray regression for competing events was 
performed. Kaplan-Meier curves were constructed to display differences in probability of event-free 
follow-up and the log-rank test applied. The Holm method was used for post-hoc comparisons of 
Kaplan-Meier curves16. All analyses were performed in Rver3.1.317 with the ‘Rcmdr’ package18 and 
utilising the ‘Rcmdrplugin.EZR’ plugin19. A two-tailed p-value < 0.05 was taken as statistically 
significant. 
Results 
174 patients were recruited and followed up for an average of 369±156 days (range 181-791). Using 
2012 criteria, 71.3% (124/174) had severe AS compared to only 39.1% (68/174) using 2017 criteria 
(Figure 1). Therefore, 56 patients (32% of total and 45% of those originally classified as severe) were 
reclassified from severe to moderate (‘Reclassified’ group).  
Baseline Characteristics 
The baseline demographic of the three groups (Moderate, Reclassified and Severe) were similar, with 
the greatest proportion of positive ETT in the reclassified group, though this was not statistically 
significant (Table-2). The characteristics for severe and moderate AS using 2012 and 2017 definitions 
are shown in Table S1. 
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Echocardiography and CT 
All patients in the Reclassified group had AVA index (AVAI)<0.6cm2, but 44.6% had AVA>1cm2. As 
expected, the Reclassified group had valve areas similar to the Severe group, but gradients similar to 
the Moderate group, with significantly lower SVI than both groups.   
Calcium scores in the Reclassified group were similar to the Moderate group and significantly lower in 
both than the severe group (Table-2). Although there was correlation between AVCalcIndex and AVA, 
AV-Vmax and MPG, scores could be low even with high MPG, AV-Vmax or low AVA (Figure S1). 
CMR  
In keeping with gradient differences, LV remodelling in the Reclassified group was of similar 
magnitude to the Moderate group, with mass/volume and LV mass index being significantly lower in 
both compared to the Severe group (Table-2). The MPR was significantly higher in the Reclassified 
and Moderate groups compared to the Severe group. There were no significant differences in LGE or 
extracellular volume fraction (ECV) and the indexed extracellular volume (iECV) between groups.  
Biomarkers 
There was a progressive increase in HsTNI values with increasing AS severity, with the levels in the 
Severe group being statistically higher than the other groups.  There was no significant difference in the 
NTproBNP levels between groups. 
Primary Endpoint 
There were 47 (27%) primary endpoints (Table-2): 41 AVR for spontaneous symptoms, 1 
cardiovascular death & 5 hospitalisations (1 chest pain, 2 dyspnoea, 1 heart failure, 1 syncope) (Figure 
S2). The Kaplan-Meier curve for event-free survival comparing the three subgroups, showed 
incrementally worse outcome from moderate to Reclassified to severe groups (Figure-2). Separate 
Kaplan-Meier curves using the 2012 and 2017 criteria are shown in Figure S3.  Univariate associations 
(unadjusted and adjusted) with the primary endpoint are presented in Table S2 and Table-3. Cox models 
showed that both the Reclassified and severe group had a significantly higher risk of reaching an 
endpoint (2.78× and 4.95× respectively), compared to the moderate group (when modelled as 
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categorical groups). However, after adjusting for a positive ETT, the Reclassified group became not 
significant (p=0.051).  
Although estimated glomerular filtration rate (eGFR), NTproBNP and MPR were significantly 
associated with the primary endpoint on univariate analysis (Table S2), none were significant after 
adjusting for sex, ETT and severe AS (2017 definition) (Table S3).  HsTNI was not associated with the 
primary endpoint, but was associated with cardiovascular death or unplanned hospitalisation, in 
competing events proportional hazards regression, even after adjusting for age, MPG or AVA and ETT 
(Table S4). 
Value of Calcium Scores 
Log-transformed calcium scores were not associated with the primary endpoint in cox models, although 
after adjusting for sex, this was significant (Table S2 and S3). Likewise, AVCalcIndex was associated 
with the end-point on univariate analyses. Unadjusted subgroup analyses suggest that AVCalcIndex 
was prognostic in females, AVA≤1cm2, AVAI≤0.6cm2/m2 and patients with positive ETT, although p-
interaction was only significant for valve areas. However it was not statistically significant after 
adjusting for AV-Vmax (Figure 3).   
Further risk stratification within the Reclassified group 
Univariate associates with primary endpoint in the Reclassified group are shown in Table-4. In this 
group, only MPG was significantly associated with the primary endpoint, whilst sex, ETT, fibrosis, 
remodelling markers and biomarkers were not. A receiver operating curve identified 31mmHg as an 
ideal cut-off value with the highest combined sensitivity and specificity for dichotomising risk (Figure 
S4). Kaplan Meier analyses using a ≥31mmHg cut-off and 5mmHg interval cut-offs between 20-
40mmHg (Figure 4) further demonstrate this. 
Hazard ratios of accepted dichotomized markers of AS severity and the more novel MPG≥31mmHg 
marker found in this cohort was compared (Table S5). MPG≥31mmHg had numerically the largest 
hazard ratio as well as the highest c-statistic, indicating better model fit.  
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Discussion 
In this manuscript, we use the 2017 European guidelines to re-classify AS severity in a well-
characterised cohort of asymptomatic patients with at least moderate AS, and assess the clinical 
characteristics and outcome of this new Reclassified group. Nearly half the participants (56/124) were 
downgraded from severe to moderate AS. There were key differences in this Reclassified group 
compared to both previously defined moderate and severe groups. The Reclassified group demonstrated 
an intermediate risk of developing a primary endpoint (mainly driven by spontaneous symptom onset), 
with intermediate troponin levels. Patients in the Reclassified group with MPG≥31 mmHg were at ~7 
times higher risk of primary endpoints; and may be a better marker of risk in this cohort compared to 
other markers of severe AS, which could be useful to clinicians in risk-stratifying within this 
intermediate risk group. 
Characteristics of reclassified patients 
The Reclassified group is a heterogenous group; all with low gradients, but some with low flow and 
less calcification, whilst others had normal flow but more calcification. As expected from the definition, 
the Reclassified group had gradients closer to the moderate group and AVA similar to severe, but with 
the lowest SVI. However, their cardiac remodelling pattern was closer to the moderate group. There 
was a non-significant trend to increasing proportions of patients with LGE, from moderate to 
Reclassified to severe groups, a feature of poor prognosis in AS20, 21. HsTNI was also incrementally 
elevated in those respective groups although the difference between the moderate and Reclassified 
group was insignificant. HsTNI has been shown to be associated with LGE and poor prognosis in AS4. 
Assessing AS severity 
In AS, we classify patients as having moderate or severe disease to aid clinical decision making. 
However, there is no single ‘number’ that should define ‘severe AS’.  Experts generally agree that 
severe AS is associated with a poorer outcome22. AV-Vmax>4m/s is associated with a much higher risk 
of progressing to AVR or death23, 24. Moderate AS is also associated with an increased event rate, with 
a hazard ratio of 1.6 when comparing AV-Vmax≥3m/s vs <3m/s25, whilst AVAI<0.6cm2/m2 is 
associated with a doubling of the risk26. The markers of AS severity can be discordant and present 
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clinicians with a ‘difficult’ decision making process27. The change in the criteria to define severe AS in 
the 2017 European guidelines reflects the uncertainty regarding the low gradient group with a low AVA.  
The updated guidance recognizes the increased risk in those with low flow with preserved EF11, but 
classifies the group with normal flow as “likely moderate AS”. Some of the low-flow group with lower 
AV calcification will also be reclassified as moderate AS. 
Our findings of an ‘intermediate’ risk and HsTNI profile in this group may have important implications 
for these patients, where decision to refer for surgery may be deferred due to their AS being classified 
as ‘moderate’. Whilst some have described a poorer prognosis in symptomatic patients with normal 
flow, low gradient,  AVA<1cm2 AS, with a significant survival benefit from AVR28, 29, others found 
these patients to have the same prognosis as moderate aortic stenosis30. We found that in this present 
study, using MPG≥31mmHg appeared to dichotomise risk of spontaneous symptoms or events better 
than the accepted 40mmHg cut-off, or any other dichotomised marker of AS severity. This finding is 
consistent with the 2017 European guidelines31 which mention that low gradient AS is more likely to 
be severe if MPG was between 30-40mmHg. This deserves more emphasis, as evidenced in this study, 
especially if the flow is normal, and could be helpful in identifying those who should be considered for 
AVR sooner. 
Value of calcium scores 
Calcium score corroborate AS severity32 and valvular calcification on echocardiography is associated 
with worse outcomes in severe asymptomatic AS33. Sex-specific calcium score could accurately identify 
severe AS, and was independently associated with valve replacement or death34, although exact cut-offs 
vary (2062/1377AU34 vs 2065/1274AU35 vs 2000/1200AU8 in males/females respectively). Our derived 
cut-offs (2269/1146) were within this range (Figure S5).  High calcium scores has been associated with 
increased mortality risk in all subgroups, including in non-severe AS36, making it a useful ‘arbiter’ of 
AS severity, and this may be particularly true when the AVA is discordant with the gradients. We found 
calcium scores to be associated with the primary endpoint only in the low valve area subgroup, but not 
after adjusting for AV-Vmax, reinforcing that calcium scores are a lesser surrogate for gradients. 
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However, one could hypothesize that calcium scores were most valuable in females with low valve 
areas but discordant gradients.  
CMR markers  
The lack of difference in CMR markers of fibrosis between the groups was surprising, because LGE is 
associated with residual risk post-AVR2. Neither ECV nor LGE were associated with the primary 
endpoint in PRIMID-AS10, which was primarily driven by spontaneous symptom onset, suggesting 
disparate mechanisms for symptom onset and fibrosis development, both of which lead to poor 
prognosis in AS. It is concerning that 42% of those with moderate AS already have LGE, rising to half 
of the severe group, similar to the findings of a recent meta-analysis showing LGE to be present in 
49.6% of AS37. The increasing levels of HsTNI between the classes further corroborates the incremental 
fibrosis4 and HsTNI was associated with cardiovascular death and unplanned hospitalisation even after 
adjusting for age, pressure gradients and a positive ETT. Development of symptoms is likely a complex 
and multifactorial process, with structural and functional remodelling playing a role, along with 
patient’s comorbidities, deconditioning and metabolic factors. The mechanisms are likely similar to 
those that impair exercise capacity. MPR is an independent predictor of aerobic exercise capacity38 and 
associated with outcome in the PRIMID study10, whilst ECV was independently associated with MPR39. 
In this study, we showed MPR to be significantly lower in the severe group, corroborating its 
importance in exercise limitation and symptom onset. 
Should surgery be offered earlier? 
As surgery becomes safer and the less invasive transcatheter option more widespread, there should be 
a drive to identify patients for early intervention before irreversible remodelling occurs. There are now 
4 trials (EVoLVeD, AVATAR, EARLY TAVR and EASY-AS) underway, testing an early intervention 
strategy in asymptomatic patients with severe AS (ClinicalTrials.gov NCT03094143, NCT02436655, 
NCT03042104, NCT04204915). Our data suggests the potential use of AVA<1.0cm2, a higher calcium 
score or MPG≥31mmHg as selection criteria for earlier intervention in the intermediate group, given 
the higher risk of developing symptoms and events. 
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Strengths and Limitations 
The PRIMID-AS study’s main strengths were its prospective, multicentre design, run to clinical trial 
standards with blinded image analysis, independent trials unit data handling and blinding of physicians 
and patients to results of their research tests. Patients referred for surgery whilst asymptomatic were not 
included in the primary endpoint. Limitations were a low sample size, most events were driven by valve 
replacement, although we were particularly interested in spontaneous symptom onset as a marker of 
high risk; all participants had EF>40% and could perform an ETT, and were all asymptomatic at 
recruitment. As such, findings cannot be generalised to patients outside of these parameters. 
Conclusions 
The 2017 European guidelines downgraded severity in 45% of patients with severe AS when compared 
to 2012 criteria. The reclassified patients have an intermediate risk of reaching the primary endpoint, 
despite having similar gradients and remodelling characteristics as the moderate group, reinforcing the 
need for careful assessment in this group. Exercise testing, AV-calcium score and utilisation of lower 
thresholds of MPG≥31mmHg may aid risk stratification. 
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Table 1: Differences in definition of severe AS with preserved systolic function between the 
guidelines 
 Variables ESC 20126 ESC 20178 
Any of A, B or C Any of A or B 
A Vmax & MPG Vmax > 4 m/s or  
MPG > 40 mmHg 
Vmax ≥ 4 m/s or  
MPG > 40 mmHg 
B AVA AVA < 1 cm2 AVA ≤ 1 cm2 and  
SVi ≤ 35 mL/m2 and  
Integrated approach 
C AVAi <0.6cm/m2 - 
 Notes - If AVA ≤ 1 cm2 and  
SVi > 35 mL/m2 unlikely  
to be severe AS,  
unless A or B satisfied 
 
Integrated Approach (Criteria increasing likelihood of low-flow severe AS):- 
Clinical Criteria Typical Symptoms without other explanation 
Age >70 
Qualitative imaging Data Left ventricular hypertrophy not due to hypertension 
Reduced LV longitudinal function without other explanation 
Quantitative imaging Data - MPG 30-40mmHg 
- AVA ≤0.8cm2 
- Low flow (SVi < 35mL/m2) confirmed by other techniques eg.  
   CMR, 3D TOE LVOT measurement, invasive data) 
- Calcium score by MSCT 
   ≥ 3000 in men or ≥ 1600 in women: Severe AS Very likely 
   ≥ 2000 in men or ≥ 1200 in women: Severe AS likely 
 
Vmax:transvalvular peak velocity, MPG:mean transvalvular pressure gradient, AVA:aortic valve area, 
AVAi:aortic valve area indexed to body surface area, SVi:Stroke volume indexed to body surface area, 
CMR:Cardiac magnetic resonance imaging, TOE:Transoesophageal echocardiography, LVOT:Left 






Table 2: Baseline characteristics and primary endpoints of PRIMID-AS patients classified by 
combined ESC 2012/17 Criteria 







n=68 P value 
Patient Demographics 
Age 64.6±14.3 65.8±13.6 67.8±12.4 0.408 
Female (%) 11 (22%) 12 (21.4%) 18 (26.5%) 0.768 
Diabetes (%) 4 (8%) 9 (16.1%) 12 (17.6%) 0.305 
Hypertension (%) 27 (54%) 32 (57.1%) 34 (50%) 0.727 
Haemoglobin(g/dL) 14.4±1.3 14.4±1.2 14.1±1.3 0.291 
eGFR (ml/min) 88.1±27 87.7±30.6 88.2±28.6 0.995 
BMI (kg/m2) 28.4±3.5 27.7±4.1 27.9±4.6 0.695 
SBP (mmHg) 145.5±19.5 146.4±22.6 148.3±21.1 0.756 
DBP (mmHg) 77±10.6 77.4±11.3 77.1±10.3 0.979 
Positive ETT (%) 14 (28.6%) 21 (37.5%) 21 (31.3%) 0.6 
Echocardiography 
Stroke Volume Index 
(ml/m2) 53.5±9.3* 41±7.3† 51.2±13.1 <0.001 
AVA (cm2) 1.4±0.2*† 1±0.2 1±0.3 <0.001 
AVAI (cm2/m2) 0.7±0.1*† 0.5±0.1 0.5±0.1 <0.001 
AV Vmax (m/s) 3.4±0.3† 3.6±0.2† 4.4±0.4 <0.001 
MPG (mmHg) 26.3±5† 29.5±4.6† 46.9±12 <0.001 
Mild AR 31 (62%) 39 (69.6%) 52 (76.5%) 0.2 
Moderate AR 2 (4%) 0 (0%) 3 (4.4%)  
Mild MR 16 (32%) 19 (33.9%) 23 (33.8%) 0.97 
Calcium Scores 
Calcium Score (AU) 1653 [783, 2573]† 1513 [1110, 2171]† 2962 [1785, 4349] <0.001 
Males Only 2064 [1385, 2708]† 1744 [1274, 2426]† 3303 [2366, 4806] <0.001 
Females Only 707 [348, 1091]† 934 [233, 1126]† 1829 [1301, 2562] 0.001 
Biomarkers 
HsTnI (pg/ml) 3.95 [2.71, 8.71]† 5.19 [3.13, 9.27]† 7.10 [5.11, 11.13] 0.005 
NTproBNP (pmol/L) 56.1 [16, 129] 46.3 [11.9, 143.5] 67.0 [21.3, 224.8] 0.407 
CMR 
LVEF (%)  56.6±4.8  56.7±4.6  56.7±5.4 0.997 
LVEDVI (ml/m2)  89±17.7  84.3±15.5  89.23±20.56 0.26 
LVESVI (ml/m2)  38.9±10.6  36.7±9.1  39.06±11.78 0.424 
LVM/LVEDV (g/ml)   0.62±0.1†   0.64±0.1†   0.71±0.1 <0.001 
LVMI (g/m2)  55±12.3†  53.7±10.8†  63±15.5 <0.001 
MPR   2.5±0.8†   2.4±0.6†   2±0.6 <0.001 
ECV  24.9±2.4  25±2.5  24.7±2.5 0.837 
iECV (ml/m2) 13.2±3.3 13.1±3.4 14.7±4.4 0.096 
LGE (Y/N) (%) 21 (42%)  27 (48.2%)  34 (50%)  0.677 
Primary Endpoint 
Y/N) (%) 6 (12%) 15 (26.8%) 26 (38.2%) 0.007 
CIRCCVIM/2020/011763D_R1 
*significant difference to ‘Reclassified’ group; †significant difference to ‘Severe’ group. BMI:Body 
mass index, SBP:systolic blood pressure, DBP:diastolic blood pressure, ETT:exercise tolerance test, 
AVA:aortic valve area, AVAI:AVA index, AV Vmax:peak velocity, MPG:mean pressure gradient, 
AR:aortic regurgitation, MR:mitral regurgitation, HsTNI:high sensitivity troponin I, NTproBNP:N-
terminal pro brain natriuretic peptide, LVEF:left ventricular ejection fraction, LVEDVI:LV end 
diastolic volume index, LVESVI:LV end systolic volume index, LVM/LVEDV:ratio of LV mass to 
end diastolic volume, LVMI:LV mass index, MPR:myocardial perfusion reserve, ECV:extra-cellular 
volume fraction, iECV:extra-cellular volume index, LGE:late gadolinium enhancement 
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Table 3: Adjusted univariate hazards of ‘reclassified’ or ‘severe AS’ groups to the primary 
endpoint compared to the ‘moderate AS’ group 
 Model 1 Model 2 
HR (95% CI) p value HR (95% CI) p value 
Reclassified* 2.78 (1.07-7.22) 0.036 2.60 (1.00-6.80) 0.051 
Severe AS* 4.95 (2.02-12.13) <0.001 5.11 (2.06-12.69) <0.001 
Female 2.10 (1.16-3.79) 0.014 2.02 (1.11-3.69) 0.022 
Positive ETT - - 2.07 (1.14-3.75) 0.017 
* compared to reference (moderate AS) group; all variables entered into model, Model 1: adjusted for 
sex, Model 2: adjusted for sex and positive ETT 
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Table 4: Univariate Cox analyses in the Reclassified subgroup 
 HR (95% CI) p.value 
Age (year) 1 (0.97-1.1) 0.37 
Female (Y/N) 1.5 (0.45-4.7) 0.53 
BSA (m2) 0.25 (0.02-3) 0.27 
eGFR (ml/min/1.73m2) 0.99 (0.97-1) 0.29 
Positive ETT (Y/N) 2.3 (0.82-6.5) 0.11 
MPG (mmHg) 1.2 (1.1-1.4) 0.007 
AV Vmax (m/s) 14 (0.92-200) 0.057 
AVA (cm2) 0.06 (0.003-1.3) 0.071 
AVAI (cm2/m2) 0.0091 (0.000014-6) 0.16 
LVEF (per % increase) 1 (0.92-1.2) 0.58 
Septal E/e’ (per unit ratio change) 0.95 (0.83-1.1) 0.44 
LVOT Area (cm2) 0.55 (0.23-1.3) 0.18 
SVI (ml/m2) 1.1 (0.97-1.2) 0.18 
LVMI (g/m2) 1 (0.97-1.1) 0.36 
LVEDVI (ml/m2) 1 (0.97-1) 0.96 
LVM/LVEDV (g/ml) 10 (0.05-2400) 0.4 
Left atrial index (ml/m2) 1 (0.98-1) 0.34 
LGE (Y/N) 1.2 (0.41-3.4) 0.76 
MPR (per unit ratio change) 0.89 (0.34-2.3) 0.81 
ECV (per unit ratio change) 1.2 (0.9-1.5) 0.26 
High Calcium score (Y/N) 1.8 (0.65-5) 0.26 
AVCalcIndex (per unit ratio change) 1.4 (0.88-2.1) 0.16 
Log2HsTnI 1.2 (0.81-1.7) 0.39 
Log2NTproBNP 1.1 (0.92-1.4) 0.23 
MPG ≥ 31mmHg (Y/N) 7 (1.96-25) 0.003 
 
Abbreviations as in Table-2. 
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Figures 
Figure 1: Severity distribution by different classification definitions 
 
Reclassified: classified as severe AS in ESC 2012 but moderate AS in ESC 2017; ESC: European 
Society of Cardiology 
  
CIRCCVIM/2020/011763D_R1 
Figure 2: Kaplan-Meier Curves for event-free probability by the three classes 
 
Moderate vs Reclassified: p=0.053, Reclassified vs Severe: p=0.053, Moderate vs Severe: p=0.0007,  
  
CIRCCVIM/2020/011763D_R1 
Figure 3: Subgroup analysis of additional prognostic value of AV Calc Index (unadjusted and 
adjusted) 
 
Unadjusted hazard ratios of AVCalcIndex in specified subgroups. Abbreviations as in Table-2 
*p-value after adjusting for AV-Vmax. 
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Figure 4: Kaplan Meier Analyses for Reclassified subgroup, grouped by MPG 
 
 
MPG:mean pressure gradient 
